Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation - February 23, 2010 - Prevnar 13

System Info - 120984  SMITH, MICHAEL J  23-Feb-2010 21:25:18  SMITHM


Submission Type: Original Application   Submission ID:  125324/0    Office: OVRR  

Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

Wyeth Pharmaceuticals Inc.          

Telecon Date/Time:  23-FEB-2010 09:08 PM                Initiated by FDA?  Yes
Telephone Number:    

Communication Categorie(s):
Labeling via FAX/e-mail


Telecon Summary:
Final draft label

FDA Participants:   Julie Vaillancourt, Collen Sweeney and Mike Smith

Non-FDA Participants:    Jack Love and Carmel Devlin

Trans-BLA Group: No

Related STNs:  None

Related PMCs:  None

Telecon Body:


From:                     Vaillancourt, Julienne 

Sent:                      Tuesday, February 23, 2010 9:08 PM

To:                          'Love Jack'; Devlin Carmel

Cc:                          Smith, Michael (CBER); Sweeney, Colleen

Subject:                Final Approved Draft Labeling

Dear Jack and Carmel,

This is to acknowledge our receipt of revised draft labeling, submitted as an official amendment to the BLA this evening (serial 91, amendment 94).  The draft labeling in this amendment replaces the version of the draft labeling received on February 19, 2010, and includes the changes, requested by CBER during the telecon earlier this evening, and thus, is the final approved draft labeling.

Thank you.


Julienne Vaillancourt, R.Ph., M.P.H.
Captain, US Public Health Service
Regulatory Reviewer
Division of Vaccines and Related Products Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
US Food and Drug Administration

Phone:    301-827-5414
Fax:        301-827-3532


THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW.  If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized.  If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 09/24/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English